From the Department of Cardiovascular Sciences, University College London (UCL), United Kingdom (B.W.); National Institute for Health Research, University College London Hospitals Biomedical Research Centre, United Kingdom (B.W.); Department of Cardiology, University of Cardiff, Wales, United Kingdom (J.R.C.); Jichi Medical School, Tochigi, Japan (K.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (D.H.Z., W.G.); Novartis Pharma AG, Basel, Switzerland (P.C.B.); Beijing Novartis Pharma Co, Ltd, Shanghai, China (Q.W.). bryan.williams@ucl.ac.uk. From the Department of Cardiovascular Sciences, University College London (UCL), United Kingdom (B.W.); National Institute for Health Research, University College London Hospitals Biomedical Research Centre, United Kingdom (B.W.); Department of Cardiology, University of Cardiff, Wales, United Kingdom (J.R.C.); Jichi Medical School, Tochigi, Japan (K.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (D.H.Z., W.G.); Novartis Pharma AG, Basel, Switzerland (P.C.B.); Beijing Novartis Pharma Co, Ltd, Shanghai, China (Q.W.).